Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.

Breast Cancer Research and Treatment
Olivia PaganiInternational Breast Cancer Study Group (IBCSG)

Abstract

The current therapeutic strategy in breast cancer is to identify a target, such as estrogen receptor (ER) status, for tailoring treatments. We investigated the patterns of recurrence with respect to ER status for patients treated in two randomized trials with 25 years' median follow-up. In the ER-negative subpopulations most breast cancer events occurred within the first 5-7 years after randomization, while in the ER-positive subpopulations breast cancer events were spread through 10 years. In the ER-positive subpopulation, 1 year endocrine treatment alone significantly prolonged disease-free survival (DFS) with no additional benefit observed by adding 1 year of chemotherapy. In the small ER-negative subpopulation chemo-endocrine therapy had a significantly better DFS than endocrine alone or no treatment. Despite small numbers of patients, "old-fashioned" treatments, and competing causes of treatment failure, the value of ER status as a target for response to adjuvant treatment is evident through prolonged follow-up.

References

Mar 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M CastiglioneA Goldhirsch
Jan 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A GoldhirschA S Coates
Mar 1, 1983·European Journal of Cancer & Clinical Oncology·V C JordanJ L Wittliff
Oct 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Castiglione-GertschJ Forbes
Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T SaphnerR Gray
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Diana CrivellariUNKNOWN International Breast Cancer Study Group
Mar 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne Hamilton, Gabriel Hortobagyi
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Donald A BerryEric P Winer
Oct 31, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN St Gallen Expert Panel Members
Aug 7, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN 10th St. Gallen conference
Dec 6, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B Thürlimann
Oct 7, 2008·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Paul GossAnn F Chambers
Jan 27, 2009·The Journal of Steroid Biochemistry and Molecular Biology·Joan S Lewis-WambiV Craig Jordan

❮ Previous
Next ❯

Citations

Jun 19, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J HuoberB Thürlimann
May 21, 2010·Journal of the National Cancer Institute·An HendrixWendy Westbroek
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer Y WoRinaa S Punglia
Oct 19, 2012·Journal of Oncology Practice·Julie A MargenthalerFrank E Johnson
Feb 15, 2014·Journal of Cancer Epidemiology·Linda Vona-DavisJame Abraham
Dec 12, 2013·World Journal of Surgery·Danielle J FitzpatrickDavid C A Walsh
Feb 24, 2011·Expert Review of Anticancer Therapy·Hatem A AzimMartine J Piccart
Oct 2, 2012·Maturitas·Alexandre Christinat, Olivia Pagani
Oct 25, 2011·The Breast : Official Journal of the European Society of Mastology·Octavi CórdobaJordi Xercavins
Oct 15, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Hatem A AzimFedro A Peccatori
Dec 26, 2009·The Breast : Official Journal of the European Society of Mastology·Rachel A Freedman, Eric P Winer
Apr 25, 2012·Obstetrics and Gynecology International·Michelle L MatthewsTerry Sarantou
May 27, 2014·Journal of Cancer Survivorship : Research and Practice·Sally A DominickH Irene Su
Apr 22, 2015·Breast Cancer Research and Treatment·Yoontaek LeeSung-Won Kim
Mar 19, 2015·Breast Cancer Research and Treatment·Karin KastPauline Wimberger
Jan 21, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco ColleoniAron Goldhirsch
Jul 31, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Otto Metzger-FilhoFatima Cardoso
Jan 24, 2018·Journal of the National Cancer Institute·Linda S LindströmUNKNOWN STO Trialists Group
Nov 27, 2019·The Oncologist·Shu-Chun ChuangChao Agnes Hsiung
Jul 7, 2018·Therapeutic Advances in Medical Oncology·Elisabetta Munzone, Marco Colleoni
Dec 23, 2020·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Marissa L G VaneMarjolein L Smidt
Feb 12, 2020·The Oncologist·Shu-Chun ChuangChao Agnes Hsiung
Nov 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J HuoberB Thürlimann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Cancer Prevention Research
Szilard AsztalosDebra A Tonetti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Stephanie J LeeAmerican Society of Clinical Oncology
© 2021 Meta ULC. All rights reserved